Table 6.

Activity of 41 and 50 Against GT-1a and GT-1b Clinical Isolates.

GT	Clinical Isolate	compd 41 EC50 ± SEM (nM)	compd 50 EC50 ± SEM (nM)
1a	H77	0.3 ± 0.03	0.65 ± 0.12
	RO-18	0.4 ± 0.05	0.5 ± 0.26
	RO-24	1.1 ± 0.23	2.5 ± 0.41
	RO-28	0.9 ± 0.05	0.2 ± 0.08
	RO-33	0.6 ± 0.09	0.7 ± 0.03
	RO-34	0.5 ± 0.02	0.4 ± 0.08
	RO-35	0.3 ± 0.09	0.5 ± 0.08
	RO-38	4.3 ± 0.07	9.5 ± 0.41
	RO-41	0.6 ± 0.17	0.27 ± 0.07
	mean	0.72	0.8
1b	Con1	0.32 ± 0.08	1.20 ± 0.27
	RO-1	0.11 ± 0.01	0.30 ± 0.06
	RO-2	0.19 ± 0.003	4.00 ± 1.63
	RO-3	0.43 ± 0.02	6.1 ± 0.12
	RO-4	0.11 ± 0.003	0.80 ± 0.16
	RO-7	0.22 ± 0.02	3.05 ± 0.37
	RO-8	0.33 ± 0.10	0.33 ± 0.10
	RO-9	0.34 ± 0.04	3.50 ± 0.41
	RO-10	0.34 ± 0.03	1.67 ± 0.33
	mean	0.26	1.6

EC₅₀ measured using transient HCV subgenomic replicon assay (n ≥ 2). SEM, Standard Error Mean * Geometric mean was calculated.